James Crowe
Faculty Member
Last active: 3/31/2020

Gold nanorod vaccine for respiratory syncytial virus.

Stone JW, Thornburg NJ, Blum DL, Kuhn SJ, Wright DW, Crowe JE
Nanotechnology. 2013 24 (29): 295102

PMID: 23799651 · PMCID: PMC3754908 · DOI:10.1088/0957-4484/24/29/295102

Respiratory syncytial virus (RSV) is a major cause of pneumonia and wheezing in infants and the elderly, but to date there is no licensed vaccine. We developed a gold nanorod construct that displayed the major protective antigen of the virus, the fusion protein (F). Nanorods conjugated to RSV F were formulated as a candidate vaccine preparation by covalent attachment of viral protein using a layer-by-layer approach. In vitro studies using ELISA, electron microscopy and circular dichroism revealed that conformation-dependent epitopes were maintained during conjugation, and transmission electron microscopy studies showed that a dispersed population of particles could be achieved. Human dendritic cells treated with the vaccine induced immune responses in primary human T cells. These results suggest that this vaccine approach may be a potent method for immunizing against viruses such as RSV with surface glycoproteins that are targets for the human immune response.

MeSH Terms (11)

Aged, 80 and over Antigens, Viral Cells, Cultured Gold Humans Immobilized Proteins Infant, Newborn Nanotubes Respiratory Syncytial Viruses Respiratory Syncytial Virus Infections T-Lymphocytes

Connections (1)

This publication is referenced by other Labnodes entities: